A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma

被引：172
|
作者：
Popat, Rakesh [1 ,2 ]
Plesner, Torben [3 ]
Davies, Faith [4 ]
Cook, Gordon [5 ]
Cook, Mark [6 ]
Elliott, Peter [7 ]
Jacobson, Eric [7 ]
Gumbleton, Todd [1 ]
Oakervee, Heather [1 ]
Cavenagh, Jamie [1 ]
机构：
[1] St Bartholomews Hosp, London, England
[2] UCL Canc Inst, London, England
[3] Vejle Hosp, Vejile, Denmark
[4] Royal Marsden Hosp, Surrey, England
[5] St James Hosp, Leeds LS9 7TF, W Yorkshire, England
[6] Queen Elizabeth Hosp, Birmingham B15 2TH, W Midlands, England
[7] GSK Co, Sirtris, Cambridge, MA USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2013年 / 160卷 / 05期
关键词：
myeloma; clinical trials; renal medicine; APOPTOSIS; PROTEINS;
D O I：
10.1111/bjh.12154
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：714 / 717
页数：4
相关论文
共 50 条
  • [21] PANORAMA 2: A phase II study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory multiple myeloma.
    Alsina, Melissa
    Schlossman, Robert L.
    Weber, Donna M.
    Coutre, Steven E.
    Lonial, Sagar
    Gasparetto, Cristina
    Warsi, Ghulam
    Ondovik, Michael S.
    Mukhopadhyay, Sutapa
    Paley, Carole S.
    Richardson, Paul Gerard Guy
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Time To Event Analyses in PANORAMA 2: A Phase 2 Study Of Panobinostat, Bortezomib, and Dexamethasone In Patients With Relapsed and Bortezomib-Refractory Multiple Myeloma
    Richardson, Paul G.
    Schlossman, Robert L.
    Alsina, Melissa
    Weber, Donna M.
    Coutre, Steven E.
    Gasparetto, Cristina
    Mukhopadhyay, Sutapa
    Ondovik, Michael S.
    Khan, Mahmudul
    Paley, Carole S.
    Lonial, Sagar
    BLOOD, 2013, 122 (21)
  • [23] Bortezomib asociated to dexamethasone in patients with relapsed/refractory multiple myeloma
    de la O, G. M. Maria
    Garcia-Delgado, R.
    Cuesta, M. A.
    Garrido, P.
    Dominguez, B.
    Hernandez, F.
    Galan, M.
    Sanchez, A.
    Garcia-Sanchez, R.
    Lopez, E.
    Perez, E.
    Bailen, A.
    Heiniger, A. I.
    Ramirez, G.
    Garcia, A.
    Jurado, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 482 - 483
  • [24] Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma
    Richardson, Paul G.
    Badros, Ashraf Z.
    Jagannath, Sundar
    Tarantolo, Stefano
    Wolf, Jeffrey L.
    Albitar, Maher
    Berman, David
    Messina, Marianne
    Anderson, Kenneth C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 150 (04) : 428 - 437
  • [25] Bortezomib in relapsed or refractory myeloma patients
    Leonetti Crescenzi, S.
    Piccioni, A. L.
    Bagnato, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 208 - 208
  • [26] A Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Kumar, Shaji
    Harrison, Simon J.
    Cavo, Michele
    De La Rubia, Javier
    Popat, Rakesh
    Gasparetto, Cristina J.
    Hungria, Vania
    Salwender, Hans J.
    Suzuki, Kenshi
    Kim, Inho
    Punnoose, Elizabeth
    Hong, Wan-Jen
    Freise, Kevin J.
    Sood, Anjla
    Jalaluddin, Muhammad
    Ross, Jeremy
    Ward, James E.
    Maciag, Paulo
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E31 - E31
  • [27] Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Ocio, Enrique M.
    Mateos, Maria-Victoria
    Prosper, Felipe
    Martin, Jesus
    Rocafiguera, Albert Oriol
    Jarque, Isidro
    Iglesias, Rebeca
    Motlloo, Cristina
    Sole, Maria
    Rodriguez-Otero, Paula
    Martinez, Sara
    Fernandez-Garcia, Eva
    Michot, Jean-Marie
    Soto-Matos, Arturo
    Diaz-Pavon, Jose Rodriguez
    Ribrag, Vincent
    Miguel, Jesus San
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma
    White, Darrell
    Kassim, Adetola
    Bhaskar, Birbal
    Yi, Jing
    Wamstad, Karen
    Paton, Virginia E.
    CANCER, 2013, 119 (02) : 339 - 347
  • [29] Preliminary Results of a Phase 2 Study of PD 0332991 in Combination with Bortezomib and Dexamethasone in Patients with Relapsed and Refractory Multiple Myeloma
    Niesvizky, Ruben
    Costa, Luciano J.
    Haideri, Nisreen A.
    Hess, Georg
    Singhal, Seema
    Spicka, Ivan
    Stadtmauer, Edward A.
    Badros, Ashraf Z.
    Raab, Marc S.
    Jakubczak, John L.
    Kim, Sindy T.
    Randolph, Sophia
    Ely, Scott A.
    Chen-Kiang, Selina
    BLOOD, 2011, 118 (21) : 1268 - 1269
  • [30] A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma
    Petrucci, Maria T.
    Giraldo, Pilar
    Corradini, Paolo
    Teixeira, Adriana
    Dimopoulos, Meletios A.
    Blau, Igor W.
    Drach, Johannes
    Angermund, Ralf
    Allietta, Nathalie
    Broer, Esther
    Mitchell, Vivien
    Blade, Joan
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 160 (05) : 649 - 659
12345